NCT05760937View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 10, 2023

Primary Completion Date

November 27, 2023

Study Completion Date

November 27, 2023

Conditions
Healthy Participants
Interventions
DRUG

BMS-986447

Specified dose on specified days

DRUG

Placebo

Specified dose on specified days

Trial Locations (1)

92801

Local Institution - 0001, Anaheim

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY